Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus LA85
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus LA85 is a specific probiotic strain developed and patented by Wecare Probiotics Co. Ltd. (Jiangsu, China). It is a live biotherapeutic product (LBP) preserved at the China General Microbiological Culture Collection Center (CGMCC No. 21802). LA85 has been investigated for multiple therapeutic applications, including the prevention of antibiotic-associated diarrhea (AAD), treatment of ulcerative colitis and inflammatory bowel disease, and reduction of blood lipids. The strain works through multiple mechanisms, including modulation of gut microbiota diversity, regulation of immune responses via the TLR4/NF-κB and Notch signaling pathways, enhancement of intestinal barrier function, and pathogen antagonism. Clinical trials have evaluated its efficacy at doses of 2 × 10^9 CFU/day for preventing amoxicillin-associated diarrhea, particularly in younger populations.
- Brand names
- WecLac
- Other names
- Lactobacillus acidophilus LA85L. acidophilus LA85
02
Targets
NF-κBNOTCH (Neurogenic locus notch homolog protein 3)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on lactobacillus acidophilus LA85.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus LA85.